Indivior loses 1 billion in capitalization as generic to Suboxone Film is approved

Indivior’s shares have declined by over 50% over the last two trading days–that is over £1bn in capitalization–after a US federal judge ruled in favor of India-based Dr Reddy’s Laboratories, which manufacture the generic version of blockbuster Suboxone Film. The ruling allows the India-based group to export its drug in the US, lifting the injunction imposed 10 months ago by another judge. The verdict will heavily affect the profits of the former Reckitt Benckiser’s spin-off, so it is now crucial to know when the Indian generic will be available in the US.

(Source: Indivior)